Policy & Regulation
TRIGR Therapeutics expands bispecific immuno-oncology range
5 December 2018 -

TRIGR Therapeutics, a privately-owned company based in Irvine, California focused on the development and commercialisation of novel therapeutics, has expanded its bispecific immuno-oncology range with the global license of a clinical stage, dual angiogenesis inhibitor from ABL Bio, it was reported on Tuesday.

Both firms have signed a collaboration and license agreement for TR009(formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic factors, VEGF and DLL4. The license agreement is exclusive and global, excluding the Republic of Korea, for all oncology indications and excluding the Republic of Korea and Japan for all ophthalmology indications. This agreement is in addition to the recently announced agreement whereby TRIGR licensed pre-clinical immune engaging bispecific antibodies from ABL.

The company is conducting a dose escalation Phase 1a study of the product at the Samsung Medical Center in South Korea.